KalVista Pharmaceuticals

KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.

Funding reportedLast round: Post ipo equity

BiopharmaCambridge, United States

What company datasets say KalVista Pharmaceuticals raised

Funding, as reported

Reported in all$458Min dollars

Rounds5

Last roundPost ipo equity

Last round dateFeb 2024

Investors listed5

Investors who name them

Each firm lists KalVista Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put KalVista Pharmaceuticals in front of investors. Or tell us what we have wrong.